Skip to main content
x

Recent articles

Bristol seeks another celmod use

Golcadomide will begin a new pivotal trial in follicular lymphoma.

Head and neck cancer is next for evorpacept

Against the odds, the CD47 inhibitor now faces two more clinical catalysts.

DualityBio tries to float again

The group expects to raise nearly $170m.

Vor looks to answer the Car-T question

Can the company add a Car-T string to its stem cell transplant bow?

Lilly’s big Jaypirca test approaches

After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.

Enhertu could fill a gastric hole

The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.